Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions
Z Megyesfalvi, CM Gay, H Popper… - CA: a cancer journal …, 2023 - Wiley Online Library
Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …
Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC
X Niu, L Chen, Y Li, Z Hu, F He - Seminars in Cancer Biology, 2022 - Elsevier
Small cell lung cancer (SCLC) is an aggressive form of lung cancer characterized by dismal
prognosis. Although SCLC may initially respond well to platinum-based chemotherapy, it …
prognosis. Although SCLC may initially respond well to platinum-based chemotherapy, it …
Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer
Y Cheng, DR Spigel, BC Cho… - … England Journal of …, 2024 - Mass Medical Soc
Background Adjuvant therapy with durvalumab, with or without tremelimumab, may have
efficacy in patients with limited-stage small-cell lung cancer who do not have disease …
efficacy in patients with limited-stage small-cell lung cancer who do not have disease …
cfDNA methylome profiling for detection and subty** of small cell lung cancers
Small cell lung cancer (SCLC) is characterized by morphologic, epigenetic and
transcriptomic heterogeneity. Subtypes based upon predominant transcription factor …
transcriptomic heterogeneity. Subtypes based upon predominant transcription factor …
Emerging strategies for the treatment of small cell lung cancer: a review
WJ Petty, L Paz-Ares - JAMA oncology, 2023 - jamanetwork.com
Importance Small cell lung cancer (SCLC) is an aggressive disease that is characterized by
rapid growth and the early development of metastases. Patients typically respond to initial …
rapid growth and the early development of metastases. Patients typically respond to initial …
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer
Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a poor
prognosis. Initial responses to standard-of-care chemo-immunotherapy are, unfortunately …
prognosis. Initial responses to standard-of-care chemo-immunotherapy are, unfortunately …
Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung
Cancer (SCLC) provide recommended management for patients with SCLC, including …
Cancer (SCLC) provide recommended management for patients with SCLC, including …
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre …
SP Aix, TE Ciuleanu, A Navarro, S Cousin… - The Lancet …, 2023 - thelancet.com
Background Lurbinectedin is a synthetic marine-derived anticancer agent that acts as a
selective inhibitor of oncogenic transcription. Lurbinectedin monotherapy (3· 2 mg/m 2 every …
selective inhibitor of oncogenic transcription. Lurbinectedin monotherapy (3· 2 mg/m 2 every …
Electrochemical neuron-specific enolase (NSE) immunosensor based on CoFe2O4@ Ag nanocomposite and AuNPs@ MoS2/rGO
Small cell lung cancer (SCLC) is highly associated with the risk of early metastasis. Neuron-
specific enolase (NSE), a biomarker of SCLC, is directly related to tumor burden and early …
specific enolase (NSE), a biomarker of SCLC, is directly related to tumor burden and early …
[HTML][HTML] SCLC: epidemiology, risk factors, genetic susceptibility, molecular pathology, screening, and early detection
We review research regarding the epidemiology, risk factors, genetic susceptibility,
molecular pathology, and early detection of SCLC, a deadly tumor that accounts for 14% of …
molecular pathology, and early detection of SCLC, a deadly tumor that accounts for 14% of …